Variable | Cumulative incidence of relapse by 48 mo (95% CI) | Overall P value |
---|---|---|

Age | 0.154 | |

>60 y (n = 28) | 54.78% (38.85-77.24) | |

≤60 y (n = 32) | 36.72% (22.49-59.95) | |

Sex | 0.577 | |

Male (n = 22) | 36.36% (20.92-63.2) | |

Female (n = 38) | 49.66% (35.45-69.55) | |

Sokal score | 0.623 | |

Low (n = 32) | 42.71% (27.88-65.3) | |

Intermediate + high (n = 25) | 49.1% (33.07-74.74) | |

Prior IFN-α | 0.637 | |

Yes (n = 17) | 41.76% (23.67-73.7) | |

No (n = 43) | 45.94% (32.65-64.64) | |

TKI treatment duration | 0.643 | |

>76 mo (n = 30) | 47.11% (32.13-69.08) | |

≤76 mo (n = 30) | 42.29% (27.10-66) | |

2G-TKI treatment duration | 0.772 | |

>39 mo (n = 29) | 44.83% (29.94-67.13) | |

≤39 mo (n = 31) | 44.31% (29.22-67.19) | |

uMR4.5 duration | 0.597 | |

>29 mo (n = 29) | 37.93% (23.81-60.42) | |

≤29 mo (n = 31) | 50.52% (35.13-72.66) | |

2G-TKI type | 0.331 | |

Dasatinib (n = 30) | 50.83% (35.52-72.76) | |

Nilotinib (n = 30) | 38.62% (29.99-62.15) | |

Prior intolerance or resistance to TKI | 0.00233 | |

Yes (n = 13) | 35.51% (23.73-53.15) | |

No (n = 47) | 76.92% (57.11-100) |

Quantitative variables were categorized into 2 groups with cutoffs set at median.

*P*< .05 was considered statistically significant.